Abstract: SA-PO144
Differences in Prevalence of Muscle Weakness (Sarcopenia) in Haemodialysis Patients Determined by Hand Grip Strength According to Variation in Sarcopenia Guidelines
Session Information
- Nutrition, Inflammation, Metabolism: Clinical Trials, Biomarkers, Epidemiology
November 04, 2017 | Location: Hall H, Morial Convention Center
Abstract Time: 10:00 AM - 10:00 AM
Category: Nutrition, Inflammation, and Metabolism
- 1401 Nutrition, Inflammation, Metabolism
Authors
- Hung, Rachel, Royal Free Hospital, London, London, United Kingdom
- Tangvoraphonkchai, Kamonwan, Chulalongkorn University, Bangkok, Thailand
- sadeghi-alavijeh, Omid, Royal Free Hospital, London, United Kingdom
- Davenport, Andrew, Royal Free Hospital, London, United Kingdom
Background
Muscle weakness is associated with increased mortality, and patients on haemodialysis (HD) are at increased risk of muscle loss. There is no universal agreed definition for muscle weakness, so we wished to determine whether using different cut off criteria recommended by clinical guideline groups altered the prevalence in HD patients.
Methods
We measured hand grip strength (HGS) in HD outpatients comparing HGS with clinical guideline cut offs (European Working Group on Sarcopenia in Older People (EWGSOP), National Institutes of Health Sarcopenia Project (FNIH)) used to define muscle wasting (sarcopenia), as well as age and gender matched normative data.
Results
We studied 459 patients, 61.4% male, 47.3% diabetic. The prevalence of muscle weakness was significantly different when measuring HGS; 84.5% using the EWGSOP cut off, 73.2% with FNIH criteria and 75.2% using North American and 56.6% UK normative data (p<0.01). On logistic regression, muscle weakness was associated with age (odds ratio (OR) 1.05, p<0.001), weight (OR 0.96, p<0.001), serum albumin (OR 0.89, p=0.007)and being a non-diabetic (OR 0.31, p=0.001) whereas gender is not a significant factor. In addition, 66.7% of patients with no-comorbidities were weak, compared to 93.8% with highest co-morbidity score, p<0.001.
Conclusion
There is currently no agreed universal definition for muscle wasting (sarcopenia), but the EWGSOP and FNIH advocate HGS cut offs as part of their definition of sarcopenia. The prevalence of muscle weakness varies according to cut off, and whether age and gender matched normative data is used. In addition, patient characteristics in terms of age and co-morbidity also determine the prevalence of muscle weakness.
Male and female cut off points for different sarcopenia guidelines.
* p<0.5, ** p<0.01 , *** p <0.001 for EWSOP vs others